Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-03-29
2005-03-29
Swartz, Rodney P (Department: 1645)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S252100, C435S320100, C435S471000, C424S257100, C424S258100
Reexamination Certificate
active
06872547
ABSTRACT:
The invention encompasses methods of maintaining desired recombinant genes in a genetic population of cells expressing the desired gene. The methods utilize microbial cells that have an inactivating mutation in a native essential gene encoding an enzyme which catalyzes a step in the biosynthesis of diaminopimelic acid (DAP). The cells also have an extrachromosomal vector that includes the desired gene and which is capable of homologous recombination with a chromosome of the microorganism. The vector also has a recombinant complementing gene encoding a functional replacement of the native essential gene. The cells of the invention are particularly useful for components of vaccines, including DNA vaccines.
REFERENCES:
patent: 4190495 (1980-02-01), Curtiss, III
patent: 4424065 (1984-01-01), Langhoff et al.
patent: 4550081 (1985-10-01), Stocker
patent: 4888170 (1989-12-01), Curtiss, III
patent: 5006335 (1991-04-01), Gluck et al.
patent: 5278744 (1994-01-01), Geboers et al.
patent: 5294441 (1994-03-01), Curtiss, III
patent: 5387744 (1995-02-01), Curtiss, III et al.
patent: 5389368 (1995-02-01), Curtiss, III
patent: 5424065 (1995-06-01), Curtiss, III et al.
patent: 5468485 (1995-11-01), Curtiss, III
patent: 5527529 (1996-06-01), Dougan et al.
patent: 5643771 (1997-07-01), Stocker
patent: 5656488 (1997-08-01), Curtiss, III et al.
patent: 5672345 (1997-09-01), Curtiss, III
patent: 5840483 (1998-11-01), Curtiss, III
patent: 5851519 (1998-12-01), Dougan et al.
patent: 5855879 (1999-01-01), Curtiss, III
patent: 5855880 (1999-01-01), Curtiss, III
patent: 5888790 (1999-03-01), Cahoon et al.
patent: 5980907 (1999-11-01), Dougan et al.
patent: 6004815 (1999-12-01), Portnoy et al.
patent: 6024961 (2000-02-01), Curtiss, III et al.
patent: WO9634631 (1996-11-01), None
Nayak et al. “A live recombinant avirulant oral salmonella vacine expressing pneumocopccal surface protein A induces protective response againstStreptococcus pneumonaie” Infection and Immunity vol. 66, No. 8 , pp. 3744-3751, 1998.*
Nayak et al. “A live recombinant avirulant oral salmonella vacine expressing pneumocopccal surface protein A induces protective response againstStreptococcus pneumonaie” Infection and Immunity vol. 66, No. 8 , pp. 3744-3751, 1998.*
Patrice Courvalin, Sylvie Goussard, Catherine Grillot-Courvalin, “Gene Transfer From Bacteria To Mammalian Cells,”Life Sciences,1995; pp. 1207-1212, 318, C.R. Adad, Paris.
Carmen Buchriesser, Phillippe Glaser, Christoph Rusniok, Hafed Nedjari, Helene D'Hauteville, Frank Kunst, Phillippe Sansonetti, and Claude Parsot, “The Virulence Plasmid pWR100 and the Repertoire of Proteins Secreted by the Type III Secretion Apparatus of Schigella Flexneri,”Molecular Biology,(2000) pp. 760-771, 38(4), Blackwell Science Ltd, Paris.
Amann and Brosius (1985)ATG vectors' for regulated high-level expression of cloned genes in Escherichia coli; Gene 40: pp. 183-190.
Buchanan et al. (1987)Characterization of Antibody-Reactive Epitopes on the 65-Kilodalton Protein of Mycobacterium leprae; Infection and Immunity vol. 55, No. 4, pp. 1000-1003.
Curtiss and Kelly (1987)Salmonella typhimurium Deletion Mutants lacking Adenylate Cyclase and Cyclic AMP Receptor Protein Are Avirulent and Immunogenic; Infection and Immunity vol. 55, No. 12, pp. 3035-3043.
Darji et al. (1997)Oral Somatic Transgene Vaccination Using Attenuated S. typhimurium; Cell, vol. 91, pp. 765-775.
Galan et al. (1990)Cloning and characterization of the asd gene of Salmonella tyhpimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains; Gene, vol. 94, pp. 29-35.
Jagusztyn-Krynicka et al. (1982)Expression of Streptococcus mutans Aspartate-Semialdehyde Dehydrogenase Gene Cloned into Plasmid pBR322; J. Gen. Microbiol. vol. 28; pp. 1135-1145.
Kahn et al. (1979)Plasmid Cloning Vehicles Derived from Plasmids ColE1, F, R6K, and RK2; Methods in Enzymology, vol. 68, pp. 268-280.
Kleckner et al. (1977)Genetic Engineering in Vivo Using Translocatable Drug-resistance Elements; J. Mol. Biol. vol. 116, pp. 125-159.
Nakayama et al. (1988)Construction of an ASD+ Expression-Cloning Vector; Biotechnol., vol. 6, pp. 693-697.
Robinson (1997)Nucleic acid vaccines: an overview; Vaccine, vol. 15, No. 8, pp. 785-787.
Sizemore et al. (1995)Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization; Science vol. 270; pp. 299-302.
Ulmer et al. (1996)DNA Vaccines Promising: A New Approach to Inducing Protective Immunity'; ASM News vol. 62, pp. 476-479.
Ulmer et al. (1996)DNA vaccines; Curr. Opin. Immunol. vol. 8, pp. 531-536.
Whalen (1996)DNA Vaccines for Emerging Infectious Diseases: What if?;Emerg. Infec. Dis. vol. 2, pp. 168-175.
Shahnan-Shah Khatol
Swartz Rodney P
Thompson & Coburn LLP
Washington University
LandOfFree
Functional balanced-lethal host-vector systems does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Functional balanced-lethal host-vector systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Functional balanced-lethal host-vector systems will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3441962